Hims & Hers Health, Inc. (HIMS)
NYSE: HIMS · Real-Time Price · USD
15.60
-0.22 (-1.39%)
At close: Feb 26, 2026, 4:00 PM EST
15.45
-0.15 (-0.96%)
After-hours: Feb 26, 2026, 7:59 PM EST
Hims & Hers Health Stock Forecast
Stock Price Forecast
The 10 analysts that cover Hims & Hers Health stock have a consensus rating of "Hold" and an average price target of $26.38, which forecasts a 69.10% increase in the stock price over the next year. The lowest target is $13.25 and the highest is $68.
Price Target: $26.38 (+69.10%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Hims & Hers Health stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 7 | 8 | 8 | 7 | 8 | 9 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 11 | 12 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $48 → $25 | Buy | Maintains | $48 → $25 | +60.26% | Feb 25, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $40 → $21 | Hold | Maintains | $40 → $21 | +34.62% | Feb 25, 2026 |
| Leerink Partners | Leerink Partners | Hold Maintains $20 → $18 | Hold | Maintains | $20 → $18 | +12.18% | Feb 24, 2026 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Feb 24, 2026 |
| Citigroup | Citigroup | Strong Sell Maintains $17 → $13 | Strong Sell | Maintains | $17 → $13 | -15.06% | Feb 24, 2026 |
Financial Forecast
Revenue This Year
2.80B
from 2.35B
Increased by 19.10%
Revenue Next Year
3.32B
from 2.80B
Increased by 18.67%
EPS This Year
0.58
from 0.51
Increased by 13.49%
EPS Next Year
0.79
from 0.58
Increased by 36.68%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.1B | 3.9B | |||
| Avg | 2.8B | 3.3B | |||
| Low | 2.4B | 2.7B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 33.5% | 39.9% | |||
| Avg | 19.1% | 18.7% | |||
| Low | 1.4% | -2.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2029 |
|---|---|---|---|
| High | 1.44 | 1.31 | |
| Avg | 0.58 | 0.79 | |
| Low | -0.07 | 0.21 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2029 |
|---|---|---|---|
| High | 180.8% | 125.7% | |
| Avg | 13.5% | 36.7% | |
| Low | - | -64.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.